Alkermes NASDAQ: ALKS is preparing for a series of clinical readouts across its orexin drug programs, with studies in sleep disorders, attention-deficit/hyperactivity disorder and fatigue expected over the next 12 months, CEO Blair Jackson said during a fireside chat.
Jackson said the company has about six mid- or late-stage programs due to report results in that period. Alkermes also plans to submit an application for LUMRYZ in idiopathic hypersomnia, or IH, following positive Phase 3 data, he said.
The CEO pointed to the acquisition of Avadel, the advancement of orexin programs into Phase 3 and recent ADHD data for ALKS 7290 as milestones. Jackson said Alkermes has generated more than $1.8 billion in revenue this year and is highly profitable, adding that the company’s focus is now on execution.
IH Readout and Narcolepsy Studies
The next major readout is a Phase 2 study in IH, a sleep disorder characterized by excessive daytime sleepiness. Jackson said results from Alkermes’ study in narcolepsy type 2, or NT2, offer a useful reference because the patient populations overlap, although some IH patients are long sleepers who may respond differently.
In the NT2 study, Jackson said, roughly 70% of patients receiving the highest once-daily dose moved from moderate-to-severe sleepiness into the normal range on the Epworth Sleepiness Scale, or ESS. The patient-reported scale measures sleepiness in everyday situations.
Jackson said a four-point change is typically considered clinically meaningful and a six-point change moderate. He added that Alkermes designed the IH study to achieve statistical significance, but would also use the results to inform a potential Phase 3 study if some groups performed differently than expected.
Alkermes also expects Phase 3 studies in narcolepsy types 1 and 2 to read out next year. Jackson said enrollment was progressing well and that the company expects results to be similar to those seen in earlier studies, though those outcomes remain unproven.
ADHD and Other Pipeline Opportunities
For ALKS 7290 in ADHD, Jackson urged caution in interpreting an earlier Phase 1b study. He said the two-week inpatient study was not placebo-controlled and was primarily intended to assess safety, dosing and whether the drug’s mechanism produced measurable effects.
Jackson said responses were consistent across several measures, including patient- and physician-reported outcomes. A larger, randomized Phase 2 dose-ranging study is designed to establish the treatment’s effect size relative to placebo, he said. Results are expected in the second half of next year.
The company is also studying fatigue in people with multiple sclerosis and Parkinson’s disease. Jackson said the Phase 2 study is intended in part to determine which fatigue measures are sufficiently sensitive for use as a primary endpoint and to inform discussions with regulators.
In major depressive disorder, Alkermes is studying both a broader patient group and a group with excessive sleepiness. Jackson said the latter could help the company identify a more targeted development path.
LUMRYZ and the Commercial Business
Jackson said Alkermes considered both generic oxybate competition and the potential arrival of orexin drugs when evaluating its Avadel acquisition. He said generics to XYREM are not substitutable for LUMRYZ and that the company has not seen the class-wide erosion it had assessed as a risk.
Orexin drugs could affect new oxybate prescriptions, Jackson said, but some patients may prefer to add an orexin treatment in the morning while continuing an oxybate at night. Alkermes plans to generate data on that approach as part of its alixorexton registration program.
Jackson also said he expects a long commercial life for VIVITROL, citing manufacturing challenges facing a potential generic competitor. For LYBALVI, he said the company’s listed patents extend into the late 2030s.
About Alkermes (NASDAQ:ALKS)
Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for neuroscience-related conditions, including serious mental illness and addiction. Founded in 1987, the company has operations in the United States and Ireland, with its corporate headquarters in Dublin and major U.S. operations in Massachusetts. Its marketed medicines include Vivitrol, an extended-release injectable formulation of naltrexone used to treat alcohol dependence and to prevent relapse to opioid dependence after detoxification; Aristada, an injectable treatment for schizophrenia in adults; and Lybalvi, a medicine for schizophrenia and bipolar I disorder in adults.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alkermes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.
While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.